Buy Altimmune's Potential Market Disruption With Pemvidutide

stockvisual/E+ via Getty Images Altimmune, Inc. (NASDAQ:ALT) is a clinical-stage biopharmaceutical company specializing in developing innovative peptide-based treatments for obesity and liver diseases, specifically Metabolic Dysfunction-Associated Steatohepatitis [MASH]. The company's drug candidate is Pemvidutide [ALT-801], which targets glucagon-like peptide-1 [GLP-1] and glucagon receptors to produce weight loss, keeping lean mass with reduced gastrointestinal side effects and cardiac events. Pemvidu ...